Oocyte Vitrification Aided With Latrunculin A

• Sponsor: Ibn Sina Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT03678571
• Collaborator: Banoon IVF Center (Other)
• Enrollment: 400
• Locations: 3
• Arms: 2
• Actual Duration (Months): 9.6
• Patients Per Site: 133.3
• Patients Per Site Per Month: 13.9

Study Details

Study Description

Brief Summary

Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification

Condition or Disease	Intervention/Treatment	Phase
Infertility	Other: Latrunculin A supplemented vitrification medium	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 400 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Other
• Official Title: Latrunculin A for Oocyte Vitrification
• Actual Study Start Date: Sep 25, 2018
• Actual Primary Completion Date: Jul 1, 2019
• Actual Study Completion Date: Jul 15, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Latrunculin A supplemented vitrification medium	Other: Latrunculin A supplemented vitrification medium; Vitrification of human oocyte in medium supplemented with Latrunculin A
No Intervention: Vitrification medium with no supplementation

Outcome Measures

Primary Outcome Measures

1. survival after thawing [6 days after thawing]

Secondary Outcome Measures

1. fertilization rate [6 days of culture]

2. Rates of blastocyst formation and quality [6 days of culture]

   Number of formed blastocyst and high-quality blastocysts per fertilized oocytes

3. embryo utilization rate [6 days of culture]

   Number of utilized embryos per fertilized oocytes

4. clinical pregnancy rate [three months]

   Number of pregnant women with fetal pulsation per recruited cycles

5. ongoing pregnancy rate [12 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 42 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• indication for oocyte cryopreservation

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Banon Assiut	Assiut		Egypt
2	Qena Fertility Center	Qena		Egypt	123456
3	IbnSina IVF Center, IbnSina Hospital	Sohag		Egypt	12345

Sponsors and Collaborators

• Ibn Sina Hospital
• Banoon IVF Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Muhammad Fawzy, IVF Lab Director, Ibn Sina Hospital
• ClinicalTrials.gov Identifier: NCT03678571
• Other Study ID Numbers: IbnSina-Oocyte-LA
• First Posted: Sep 19, 2018
• Last Update Posted: Jul 16, 2019
• Last Verified: Jul 1, 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Infertility

Study Results

No Results Posted as of Jul 16, 2019